# Beta Bionics, Inc.: overview
BBNX · Nasdaq · CIK 1674632 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31
Pages: [Overview](/companies/bbnx.md) · [Financials](/companies/bbnx/financials.md) · [Filings](/companies/bbnx/filings.md) · [Insiders](/companies/bbnx/insiders.md)
Latest reported revenue: [$35.5m](/filings/0001674632-26-000003.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001674632-26-000003).
## Last eight quarters
| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.4 d](/filings/0001193125-26-067065.md) | [17.6](/filings/0001193125-26-166843.md) | [23.2](/filings/0001193125-26-323777.md) | [27.3](/filings/0001674632-26-000003.md) | [32.1 d](/filings/0001193125-26-067065.md) | [27.6](/filings/0001193125-26-166843.md) | [32.0](/filings/0001193125-26-323777.md) | [35.5](/filings/0001674632-26-000003.md) |
| Gross margin | % | [57.2% d](/filings/0001193125-26-067065.md) | [50.9%](/filings/0001193125-26-166843.md) | [53.8%](/filings/0001193125-26-323777.md) | [55.5%](/filings/0001674632-26-000003.md) | [59.0% d](/filings/0001193125-26-067065.md) | [59.5%](/filings/0001193125-26-166843.md) | [59.0%](/filings/0001193125-26-323777.md) | [57.3%](/filings/0001674632-26-000003.md) |
| Operating margin | % | [(63.8%) d](/filings/0001193125-26-067065.md) | [(105.7%)](/filings/0001193125-26-166843.md) | [(85.5%)](/filings/0001193125-26-323777.md) | [(62.5%)](/filings/0001674632-26-000003.md) | [(50.2%) d](/filings/0001193125-26-067065.md) | [(87.9%)](/filings/0001193125-26-166843.md) | [(79.9%)](/filings/0001193125-26-323777.md) | [(74.9%)](/filings/0001674632-26-000003.md) |
| Net margin | % | [(88.6%) d](/filings/0001193125-26-067065.md) | [(162.5%)](/filings/0001193125-26-166843.md) | [(72.6%)](/filings/0001193125-26-323777.md) | [(52.1%)](/filings/0001674632-26-000003.md) | [(41.9%) d](/filings/0001193125-26-067065.md) | [(79.3%)](/filings/0001193125-26-166843.md) | [(73.1%)](/filings/0001193125-26-323777.md) | [(68.6%)](/filings/0001674632-26-000003.md) |
| Diluted EPS | $ per share | not reported | [(0.93)](/filings/0001193125-26-166843.md) | [(0.39)](/filings/0001193125-26-323777.md) | [(0.33)](/filings/0001674632-26-000003.md) | not reported | [(0.49)](/filings/0001193125-26-166843.md) | [(0.53)](/filings/0001193125-26-323777.md) | [(0.52)](/filings/0001674632-26-000003.md) |
| Free cash flow | $m | [(14.8) d](/filings/0001193125-26-067065.md) | [(20.3)](/filings/0001193125-26-166843.md) | [(15.4) d](/filings/0001193125-26-323777.md) | [(10.0) d](/filings/0001674632-26-000003.md) | [(10.5) d](/filings/0001193125-26-067065.md) | [(25.2)](/filings/0001193125-26-166843.md) | [(15.7) d](/filings/0001193125-26-323777.md) | [(14.6) d](/filings/0001674632-26-000003.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.
## Last five fiscal years
| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [12.0](/filings/0000950170-25-046762.md) | [65.1](/filings/0001193125-26-067065.md) | [100](/filings/0001193125-26-067065.md) |
| Gross margin | % | [52.6%](/filings/0000950170-25-046762.md) | [55.1%](/filings/0001193125-26-067065.md) | [55.4%](/filings/0001193125-26-067065.md) |
| Operating margin | % | [(298.9%)](/filings/0000950170-25-046762.md) | [(69.5%)](/filings/0001193125-26-067065.md) | [(71.5%)](/filings/0001193125-26-067065.md) |
| Net margin | % | [(367.6%)](/filings/0000950170-25-046762.md) | [(84.1%)](/filings/0001193125-26-067065.md) | [(73.0%)](/filings/0001193125-26-067065.md) |
| Diluted EPS | $ per share | [(8.31)](/filings/0000950170-25-046762.md) | [(8.60)](/filings/0001193125-26-067065.md) | [(1.81)](/filings/0001193125-26-067065.md) |
| Free cash flow | $m | [(32.8)](/filings/0000950170-25-046762.md) | [(51.7)](/filings/0001193125-26-067065.md) | [(56.2)](/filings/0001193125-26-067065.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.
## Insider purchases and sales
The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bbnx/insiders.md)
| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-27 | [Mensinger Mike](/insiders/2048500.md) | Chief Product Officer, Officer | Sale (S) | 2,650 | $22.00 | $58.3k | [Form 4](/filings/0002048500-26-000015.md) |
| 2026-10-26 | [Hopman Mark](/insiders/2048497.md) | Chief Commercial Officer, Officer | Sale (S) | 821 | $20.00 | $16.4k | [Form 4](/filings/0002048497-26-000023.md) |
## Funds that report holding it
From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $98.1m | 6,253,673 | | Added +308,185 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $68.8m | 4,393,714 | | Added +39,213 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $66.9m | 4,266,822 | | Added +39,188 |
| [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $58.1m | 3,708,043 | | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $52.3m | 3,340,171 | | Added +301,576 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $35.3m | 2,254,683 | | Reduced −270,357 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $27.9m | 1,782,346 | | Added +54,369 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $25.1m | 1,600,000 | | Reduced −611,518 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $23.5m | 1,500,000 | | Reduced −500,000 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $20.7m | 1,324,000 | | Unchanged |
## Recent filings
[All 280 filings](/companies/bbnx/filings.md)
| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 16:20 ET | [10-Q](/filings/0001674632-26-000003.md) | Quarterly report, period 2026-09-30 | 0001674632-26-000003 |
| 2026-10-27 | 16:04 ET | [8-K](/filings/0001171843-26-006856.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-006856 |
| 2026-09-17 | 18:24 ET | [8-K](/filings/0001193125-26-393322.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-393322 |
| 2026-09-15 | 16:58 ET | [8-K](/filings/0001193125-26-392088.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-392088 |
| 2026-07-29 | 16:20 ET | [10-Q](/filings/0001193125-26-323777.md) | Quarterly report, period 2026-06-30 | 0001193125-26-323777 |
| 2026-07-29 | 16:04 ET | [8-K](/filings/0001171843-26-005010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005010 |
| 2026-05-22 | 16:05 ET | [8-K](/filings/0001171843-26-003648.md) | 5.07 Shareholder vote results | 0001171843-26-003648 |
| 2026-05-21 | 16:06 ET | [8-K](/filings/0001171843-26-003617.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-003617 |
| 2026-04-21 | 16:20 ET | [10-Q](/filings/0001193125-26-166843.md) | Quarterly report, period 2026-03-31 | 0001193125-26-166843 |
| 2026-04-21 | 16:05 ET | [8-K](/filings/0001171843-26-002614.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-002614 |
## Latest annual report
[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-067065.md), filed Feb 24, 2026.
## Forecast league
Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/a37b6eb1-93c6-43a7-92c7-b9988ace0843)
## About the filer
- CIK: 1674632
- Tickers: BBNX
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:23 ET. No prices; not investment advice.